BBK Worldwide Opens West Coast Office
BBK Worldwide, patient recruitment leader and clinical research and development consultancy, announces the opening of a West Coast office in Los Angeles. This expansion is a response to increasing demands from biotechnology/biopharmaceutical research sponsors for worldwide coverage to successfully meet recruitment deadlines. Building on the 2009 office opening of BBK Worldwide – Osaka in Japan, and adding to BBK’s existing global alliance network and Boston, London, and Prague locations, the Los Angeles office creates an opportunity for BBK to better serve clients in the Pacific time zone.
According to BBK Founding Principal Joan F. Bachenheimer, “Our West Coast clients operate in a hotbed of biopharmaceutical innovation. BBK’s on-site consultation better ensures their trials are primed for success with early recruitment strategies, technology, training, and tactical implementation support.”
On assignment from BBK’s global mobilization team, project and marketing experts will staff and augment the West Coast workforce, as needed, to respond directly to client and campaign needs. “Putting ‘feet on the street’ via a West Coast office means that we can better partner with clinical team leads as well as provide immediate, and if necessary, on-site enrollment coaching and training to study coordinators and site staff,” Bachenheimer added.
BBK Director of Strategic Development Andrew N. Sacher, Esq. commented, “We are finding with our presence in Osaka that real-time BBK availability in a region focused on biopharmaceutical innovation empowers clients to invest in the most advanced patient recruitment techniques. By opening the West Coast office, we anticipate spurring similar interest and commitment to enhancing clinical trial enrollment – particularly as the sheer number of biopharmaceutical studies being conducted continues to rise.”
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
